Amidino compounds useful as nitric oxide synthase inhibitors

A method for the treatment or prevention of an inflammation-related disorder wherein the method comprises treating a subject in need thereof with an inflammation-related disorder-treating or preventing amount of a compound or a pharmaceutically acceptable salt thereof, the compound having a structure corresponding to Formula 1:

• wherein:
• X is selected from the group consisting of —S—, —S(O)—, and —S(O)2—;
• R2 is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C5 alkoxy-C1 alkyl, and C1-C5 alkylthio-C1 alkyl;
• with respect to R3 and R8:
• R8 is selected from the group consisting of —OR14 and —N(R15)(R16);
• and R3 is selected from the group consisting of —H, —OH, —C(O)—R17, —C(O)—O—R18, and —C(O)—S—R19;
• or
• R8 is —N(R20)—, and R3 is —C(O)—, wherein R8 and R3 together with the atoms to which they are attached form a ring;
• or
• R8 is —O—, and R3 is —C(R21)(R22)—, wherein R8 and R3 together with the atoms to which they are attached form a ring;
• if R3 is —C(R21)(R22)—, then R4 is —C(O)—O—R23;
• otherwise R4 is —H;
• R1, R5, R6, and R7 independently are selected from the group consisting of —H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and C1-C5 alkoxy-C1 alkyl;
• R9 and R10 independently are selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and C1-C5 alkoxy-C1 alkyl;
• with respect to R11 and R12:
• R11 is selected from the group consisting of —H, —OH, —C(O)—O—R24, and —C(O)—S—R25;
• and R12 is selected from the group consisting of —H, —OH, —C(O)—O—R26, and —C(O)—S—R27;
• or
• R11 is —O—, and R12 is —C(O)—, wherein R11 and R12 together with the atoms to which they are attached form a ring;
• or
• R11 is —C(O)—, and R12 is —O—, wherein R11 and R12 together with the atoms to which they are attached form a ring;
• and
• R13 is C1 alkyl;
• R14 is selected from the group consisting of —H and C1-C6 alkyl;
• wherein when R14 is C1-C6 alkyl, R14 is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;
• with respect to R15 and R16:
• R15 is selected from the group consisting of —H, alkyl, and alkoxy;
• and R16 is selected from the group consisting of —H, —OH, alkyl, alkoxy, —C(O)—R27a, —C(O)—O—R28, and —C(O)—S—R29;
• wherein when R15 and R16 independently are alkyl or alkoxy, R15 and R16 independently are optionally substituted with one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;
• or
• R15 is —H;
• and R16 is selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;
• R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R27a, R28, and R29 independently are selected from the group consisting of —H and alkyl, wherein alkyl is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;
• with the proviso that when R2 is methyl, then R1, R3, R4, R5, R6, R7, R9, R10, R11, R12, and R14 are not simultaneously H, and
• when any of R1, R2, R3, R4, R5, R6, R7, R9, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R27a, R28, and R29 independently is a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, aryl, and heteroaryl, then the moiety is optionally substituted by one or more substituent selected from the group consisting of —OH, alkoxy, and halogen.